People and Business News —10/22
People
Alliance Pharma expanded their leadership team by four, bringing on board a new Chief Operating Officer in Jean Pierre Boutrand, Chief Commercial Officer in Vito Saccente, Chief Financial Officer in Glenn Weber, and Susan Woolley as Chief People Officer.
Paradigm Clinical Research announced the appointment of Kurt Mussina as CEO. Additonally, the company announced growth on its executive leadership team, bringing on board Travis Milnes as chief financial officer and Amy Henderson as head of clinical operations.
Sharp, has appointed Robert Feltz as Director, Analytical and Formulation Services and Michael MacNeir as Vice President, Global Business Development.
Trialbee announced the addition of Jo Holton as VP of Global Sales to their company.
TransCelerate announced that, previously COO, Janice Chang, has been appointed Chief Executive Officer.
Business
Recbio Technology Co. contracted OCT Clinical to carry out its phase III clinical study for a SARS-CoV-2 vaccine.
Stayble Therapeutics and OCT Clinical reported that the last patient has been enrolled in the ongoing phase IIb clinical trial of STA363.
dMed |Clinipace announced that it is changing its corporate name to Caidya (pronounced KAY-dee-uh).
Recognition
CluePoints celebrated its tenth anniversary.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
